Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer

OBJECTIVE: Foretinib (GSK1363089 or XL880), which is an oral multikinase inhibitor developed to primarily target the hepatocyte growth factor (HGF)/Met signaling pathway, has shown anti-tumor effects against some cancers in preclinical and clinical studies. RESULTS: HGF/Met signaling in endometrial...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Kogata, Yuhei, Tanaka, Tomohito, Ono, Yoshihiro J., Hayashi, Masami, Terai, Yoshito, Ohmichi, Masahide
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2018
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5978264/
https://ncbi.nlm.nih.gov/pubmed/29854314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25232
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg